[ivory-search id="127" title="Default Search Form"]

NCI Director Dr. Monica Bertagnolli
Delivers First Public Speech at
ECOG-ACRIN Meeting

Learn More

The Patient Voice: Hear From
ECOG-ACRIN’s Cancer Research Advocates

Watch Video

Fall 2022 Group Meeting

This meeting has ended. Both in-person and virtual attendees may browse session agendas and view select recordings on demand.

Attendee Hub

Medical supplies and emergency support to the people of Ukraine

Learn More and Donate

Group Meetings

Group-wide meetings of the ECOG-ACRIN Cancer Research Group occur twice a year, in the spring and fall. Learn more about the purpose of these meetings and view future dates.

Learn More

NCI-MATCH Precision Medicine Trial

Seeking patients with any cancer type, including rare. Eligibility depends on tumor gene testing.

Learn More

TMIST Breast Cancer Screening Trial

Currently enrolling healthy women ages 45 to 74 throughout the United States, Canada, and a few international locations. This trial will lead to individualized screening strategies based on each woman’s risk factors.

Learn More

Early Detection of Pancreas Cancer

Most pancreatic cysts do not turn into cancer--yet the few that do can be deadly. This trial is currently recruiting people with pancreatic cysts and will screen them for five years to identify the most effective monitoring strategy.

Learn More

Search All Active Clinical Trials

Featured Trial
Leukemia Treatment

Featured Trial
Esophagus and Stomach Cancer Treatment

Featured Trial
Liver Cancer Treatment

Featured Trial
Survey on COVID-19 Related Distress

Featured Trial
Self-Reported Data by Young Adults

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Resources for Active Trials

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
PRO Research Overview

Specialty Presentation:
Implementation Science

Latest News

October 28, 2022

Categories

Press Releases

Press Release: NCI Director Monica Bertagnolli delivers her first public speech at the ECOG-ACRIN Cancer Research Group meeting

October 26, 2022

Categories

Press Releases

Press Release: NCI-MATCH cancer trial finds a promising signal for the AKT inhibitor ipatasertib

October 21, 2022

Categories

Press Releases

Press Release: Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting to assess the stage of disease more accurately using standard CT scans

October 20, 2022

Categories

Announcements

Press Release: ECOG-ACRIN taps the University of Pennsylvania’s Selina Luger to lead its Leukemia Committee

October 13, 2022

Categories

Announcements

The September/October 2022 News from ECOG-ACRIN blog is now available

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

25 Nov

The clinical effectiveness of current strategies to monitor pancreatic cysts is unknown. #ClinicalTrial EA2185 aims to compare two common approaches & identify which leads to better outcomes. Learn more: https://bit.ly/ea2185 #PancreaticCancer #PANCaware

Reply on Twitter 1596202601342676992 Retweet on Twitter 1596202601342676992 Like on Twitter 1596202601342676992 Twitter 1596202601342676992

ECOG-ACRIN Cancer Research Group @eaonc ·

25 Nov

.@myelomaMD of @mayoclinic, is leading a clinical trial to explore an additional treatment for patients with #myeloma who are at high risk of recurrence. For more: https://bit.ly/EAA171OPTIMUM #mmsm cc: @mtmdphd @VincentRK

Reply on Twitter 1596187757151342597 Retweet on Twitter 1596187757151342597 2 Like on Twitter 1596187757151342597 Twitter 1596187757151342597

ECOG-ACRIN Cancer Research Group @eaonc ·

25 Nov

Do you have locally advanced #rectalcancer (MSI-H or dMMR)? If so, you may be able to participate in a study of a potential new treatment. Learn more about the EA2201 #clinicaltrial: https://bit.ly/ea2201trial #colorectalcancer #crcsm

Reply on Twitter 1596157548608262149 Retweet on Twitter 1596157548608262149 Like on Twitter 1596157548608262149 Twitter 1596157548608262149

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1300

Participating Institutions

International Sites

15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).